Urinary excretion of RAS, BMP, and WNT pathway components in diabetic kidney disease

Physiological Reports

Volumn 2, Issue 5, 2014, Pages

  Afkarian, Maryam ^a   Hirsch, Irl B ^a   Tuttle, Katherine R ^a,b   Greenbaum, Carla ^c   Himmelfarb, Jonathan ^a   De Boer, Ian H ^a,d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SACRED HEART MEDICAL CENTER   (United States)

^c Benaroya Research Center   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

BMP pathway; Diabetic kidney disease; Pathophysiology; Renin angiotensin system; WNT pathway

Indexed keywords

ANGIOTENSINOGEN; BONE MORPHOGENETIC PROTEIN; CANDESARTAN; CREATININE; GREMLIN 1; MATRILYSIN; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASSAY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; HUMAN; IMMUNOASSAY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY CONCENTRATING CAPACITY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; POPULATION; PROTEIN URINE LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; URINARY EXCRETION; WNT SIGNALING PATHWAY;

EID: 85002829659     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.14814/phy2.12010     Document Type: Article

References (47)

1. Afkarian, M., M. C. Sachs, B. Kestenbaum, I. B. Hirsch, K. R. Tuttle, J. Himmelfarb, et al. 2013. Kidney disease and increased mortality risk in type 2 diabetes. J. Am. Soc. Nephrol. 24:302-308.
2. De Boer, I. H., T. C. Rue, P. A. Cleary, J. M. Lachin, M. E. Molitch, M. W. Steffes, et al. 2011a. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Arch. Intern. Med. 171:412-420.
3. De Boer, I. H., T. C. Rue, Y. N. Hall, P. J. Heagerty, N. S. Weiss, and J. Himmelfarb. 2011b. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 305:2532-2539.
4. Cohen, C. D., M. T. Lindenmeyer, F. Eichinger, A. Hahn, M. Seifert, A. G. Moll, et al. 2008. Improved elucidation of biological processes linked to diabetic nephropathy by single probe-based microarray data analysis. PLoS ONE 3: e2937.
5. Dai, C., D. B. Stolz, L. P. Kiss, S. P. Monga, L. B. Holzman, and Y. Liu. 2009. Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria. J. Am. Soc. Nephrol. 20:1997-2008.
6. De Petris, L., K. A. Hruska, S. Chiechio, and H. Liapis. 2007. Bone morphogenetic protein-7 delays podocyte injury due to high glucose. Nephrol. Dial. Transplant. 22:3442-3450.
7. Dolan, V., M. Murphy, D. Sadlier, D. Lappin, P. Doran, C. Godson, et al. 2005. Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy. Am. J. Kidney Dis. 45:1034-1039.
8. Groop, P. H., M. C. Thomas, J. L. Moran, J. Waden, L. M. Thorn, V. P. Makinen, et al. 2009. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 58:1651-1658.
9. Hao, S., W. He, Y. Li, H. Ding, Y. Hou, J. Nie, et al. 2011. Targeted inhibition of beta-catenin/CBP signaling ameliorates renal interstitial fibrosis. J. Am. Soc. Nephrol. 22:1642-1653.
10. He, W., C. Dai, Y. Li, G. Zeng, S. P. Monga, and Y. Liu. 2009. Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J. Am. Soc. Nephrol. 20:765-776.
11. He, W., Y. S. Kang, C. Dai, and Y. Liu. 2011. Blockade of Wnt/ beta-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J. Am. Soc. Nephrol. 22:90-103.
12. He, W., R. J. Tan, Y. Li, D. Wang, J. Nie, F. F. Hou, et al. 2012. Matrix metalloproteinase-7 as a surrogate marker predicts renal Wnt/beta-catenin activity in CKD. J. Am. Soc. Nephrol. 23:294-304.
13. Hellemons, M. E., F. Persson, S. J. Bakker, P. Rossing, H. H. Parving, D. De Zeeuw, et al. 2011. initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial. Diabetes Care 34: 2078-2083.
14. Holtkamp, F. A., D. De Zeeuw, P. A. de Graeff, G. D. Laverman, T. Berl, G. Remuzzi, et al. 2011. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. Eur. Heart J. 32:1493-1499.
15. Jang, H. R., Y. J. Lee, S. R. Kim, S. G. Kim, E. H. Jang, J. E. Lee, et al. 2012. Potential role of urinary angiotensinogen in predicting antiproteinuric effects of angiotensin receptor blocker in non-diabetic chronic kidney disease patients: a preliminary report. Postgrad. Med. J. 88:210-216.
16. Kato, H., A. Gruenwald, J. H. Suh, J. H. Miner, L. Barisoni-Thomas, M. M. Taketo, et al. 2011. Wnt/ beta-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival. J. Biol. Chem. 286:26003-26015.
17. Kim, S. S., S. H. Song, I. J. Kim, J. Y. Yang, J. G. Lee, I. S. Kwak, et al. 2012. Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patients. Diabetes Res. Clin. Pract. 97:251-257.
18. Kobori, H., L. M. Harrison-Bernard, and L. G. Navar. 2002. Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney Int. 61:579-585.
19. Kobori, H., A. Nishiyama, L. M. Harrison-Bernard, and L. G. Navar. 2003. Urinary angiotensinogen as an indicator of intrarenal Angiotensin status in hypertension. Hypertension 41:42-49.
20. Kobori, H., N. Ohashi, A. Katsurada, K. Miyata, R. Satou, T. Saito, et al. 2008. Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases. J. Am. Soc. Hypertens. 2:349-354.
21. Krolewski, A. S., J. H. Warram, A. R. Christlieb, E. J. Busick, and C. R. Kahn. 1985. The changing natural history of nephropathy in type I diabetes. Am. J. Med. 78:785-794.
22. Lai, K. N., J. C. Leung, K. B. Lai, W. Y. To, V. T. Yeung, and F. M. Lai. 1998. Gene expression of the renin-angiotensin system in human kidney. J. Hypertens. 16:91-102.
23. Liu, F., M. L. Brezniceanu, C. C. Wei, I. Chénier, S. Sachetelli, S. L. Zhang, et al. 2007. Overexpression of angiotensinogen increases tubular apoptosis in diabetes. J. Am. Soc. Nephrol. 19:269-280.
24. McMahon, R., M. Murphy, M. Clarkson, M. Taal, H. S. Mackenzie, C. Godson, et al. 2000. IHG-2, a mesangial cell gene induced by high glucose, is human gremlin. Regulation by extracellular glucose concentration, cyclic mechanical strain, and transforming growth factor-beta1. J. Biol. Chem. 275:9901-9904.
25. Miyazaki, Y., H. Ueda, T. Yokoo, Y. Utsunomiya, T. Kawamura, T. Matsusaka, et al. 2006. Inhibition of endogenous BMP in the glomerulus leads to mesangial matrix expansion. Biochem. Biophys. Res. Commun. 340:681-688.
26. Nathan, D. M., B. Zinman, P. A. Cleary, J. Y. Backlund, S. Genuth, R. Miller, et al. 2009. Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch. Intern. Med. 169:1307-1316.
27. Nishiyama, A., Y. Konishi, N. Ohashi, T. Morikawa, M. Urushihara, I. Maeda, et al. 2011. Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy. Nephrol. Dial. Transplant. 26:170-177.
28. Ogawa, S., H. Kobori, N. Ohashi, M. Urushihara, A. Nishiyama, T. Mori, et al. 2009. Angiotensin II type 1 receptor blockers reduce urinary angiotensinogen excretion and the levels of urinary markers of oxidative stress and inflammation in patients with type 2 diabetic nephropathy. Biomark Insights 4:97-102.
29. Ohashi, N., M. Urushihara, R. Satou, and H. Kobori. 2010. Glomerular angiotensinogen is induced in mesangial cells in diabetic rats via reactive oxygen species-ERK/JNK pathways. Hypertens Res. 33:1174-1181.
30. Orchard, T. J., A. M. Secrest, R. G. Miller, and T. Costacou. 2010. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 53:2312-2319.
31. Rooney, B., H. O’Donovan, A. Gaffney, M. Browne, N. Faherty, S. P. Curran, et al. 2011. CTGF/CCN2 activates canonical Wnt signalling in mesangial cells through LRP6: implications for the pathogenesis of diabetic nephropathy. FEBS Lett. 585:531-538.
32. Roxburgh, S. A., J. J. Kattla, S. P. Curran, Y. M. O’Meara, C. A. Pollock, R. Goldschmeding, et al. 2009. Allelic depletion of grem1 attenuates diabetic kidney disease. Diabetes 58:1641-1650.
33. Saha, S. A., B. K. LaSalle, G. D. Clifton, R. A. Short, and K. R. Tuttle. 2010. Modulation of advanced glycation end products by candesartan in patients with diabetic kidney disease-a dose-response relationship study. Am. J. Ther. 17:553-558.
34. Saito, T., M. Urushihara, Y. Kotani, S. Kagami, and H. Kobori. 2009. Increased urinary angiotensinogen is precedent to increased urinary albumin in patients with type 1 diabetes. Am. J. Med. Sci. 338:478-480.
35. Singh, R., A. K. Singh, and D. J. Leehey. 2005. A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli. Am. J. Physiol. Renal. Physiol. 288:F1183-1190.
36. Sugimoto, H., G. Grahovac, M. Zeisberg, and R. Kalluri. 2007. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 56:1825-1833.
37. Sugimoto, H., V. S. LeBleu, D. Bosukonda, P. Keck, G. Taduri, W. Bechtel, et al. 2012. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat. Med. 18:396-404.
38. Turk, T., J. W. Leeuwis, J. Gray, S. V. Torti, K. M. Lyons, T. Q. Nguyen, et al. 2009. BMP signaling and podocyte markers are decreased in human diabetic nephropathy in association with CTGF overexpression. J. Histochem. Cytochem. 57:623-631.
39. Walsh, D. W., S. A. Roxburgh, P. McGettigan, C. C. Berthier, D. G. Higgins, M. Kretzler, et al. 2008. Co-regulation of Gremlin and Notch signalling in diabetic nephropathy. Biochim. Biophys. Acta 1782:10-21.
40. Wang, S. N., J. Lapage, and R. Hirschberg. 2001. Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J. Am. Soc. Nephrol. 12:2392-2399.
41. Wang, S., Q. Chen, T. C. Simon, F. Strebeck, L. Chaudhary, J. Morrissey, et al. 2003. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int. 63:2037-2049.
42. Wang, S., M. de Caestecker, J. Kopp, G. Mitu, J. Lapage, and R. Hirschberg. 2006. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J. Am. Soc. Nephrol. 17:2504-2512.
43. Yamamoto, T., T. Nakagawa, H. Suzuki, N. Ohashi, H. Fukasawa, Y. Fujigaki, et al. 2007. Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J. Am. Soc. Nephrol. 18:1558-1565.
44. Yeh, C. H., C. K. Chang, M. F. Cheng, H. J. Lin, and J. T. Cheng. 2009. Decrease of bone morphogenetic protein-7 (BMP-7) and its type II receptor (BMP-RII) in kidney of type 1-like diabetic rats. Horm. Metab. Res. 41:605-611.
45. Zeisberg, M., J. Hanai, H. Sugimoto, T. Mammoto, D. Charytan, F. Strutz, et al. 2003. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat. Med. 9:964-968.
46. Zhang, Q., Y. Shi, J. Wada, S. M. Malakauskas, M. Liu, Y. Ren, et al. 2010. In vivo delivery of Gremlin siRNA plasmid reveals therapeutic potential against diabetic nephropathy by recovering bone morphogenetic protein-7. PLoS ONE 5:e11709.
47. Zhou, T., X. He, R. Cheng, B. Zhang, R. R. Zhang, Y. Chen, et al. 2012. Implication of dysregulation of the canonical wingless-type MMTV integration site (WNT) pathway in diabetic nephropathy. Diabetologia 55:255-266.